LLY - Lilly(Eli) & Co Stock Analysis
Lilly(Eli) & Co (LLY) is a publicly traded company listed on the NYSE. It operates in the Drug Manufacturers - General industry, part of the broader Healthcare sector. The company has a market capitalization of 887.63B, generates annual revenue of 65.18B, and reports net income of 20.64B. As of the latest data, the stock is trading at 939.47 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is trading at a high valuation compared to the market average, suggesting investor optimism or growth expectations. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company uses a significant amount of debt to finance its operations, which can boost returns but adds financial risk. The dividend yield (0.75%) is modest, often associated with growth-oriented companies. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Buy (4.05), indicating current market sentiment. Institutional ownership is reported at 74.23%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 30.32%, trading within a 52-week range of 623.78 - 1133.95.
LLY - Lilly(Eli) & Co
939.47
Analyst Consensus
Buy 4.05
LLY – Analyst Rating Summary
- Strong Buy: 12
- Buy: 18
- Hold: 8
- Sell: 1
- Strong Sell: 0
- Total Analysts: 39
| Index: | S&P 500 | P/E: | 41.59 | EPS (ttm): | 22.59 | Insider Own: | 9.96% | Shs Outstand: | 944.80M | Perf Week: | 0.42% |
| Market Cap: | 887.63B | Forward P/E: | 22.39 | EPS next Y: | 41.96 | Insider Trans: | -2.73% | Shs Float: | 850.75M | Perf Month: | -6.04% |
| Income(ttm): | 20.64B | PEG: | 0.84 | EPS next Q: | 7.07 | Inst Own: | 74.23% | Short Float: | 0.91% | Perf Quarter: | -13.43% |
| Revenue(ttm): | 65.18B | P/S: | 13.62 | EPS this Y: | 41.97% | Inst Trans: | 1.15% | Short Ratio: | 2.45 | Perf Half Y: | 11.09% |
| Book/sh: | 28.09 | P/B: | 33.45 | EPS next Y: | 22.08% | ROA: | 21.59% | Short Interest: | 7.70M | Perf Year: | 30.32% |
| Cash/sh: | 7.69 | P/C: | 122.13 | EPS next 5Y: | 26.59% | ROE: | 101.35% | 52W Range: | 623.78 - 1133.95 | Perf YTD: | -12.58% |
| Dividend Est.: | 7.04 (0.75%) | P/FCF: | 98.93 | EPS past 3/5Y: | 49.25% 27.59% | ROIC: | 30.11% | 52W High: | 1133.95 -17.15% | Beta: | 0.53 |
| Dividend TTM: | 6.23 (0.66%) | Quick Ratio: | 1.19 | Sales past 3/5Y: | 31.69% 21.58% | Gross Margin: | 83.04% | 52W Low: | 623.78 50.61% | Perf 5Y: | 409.23% |
| Dividend Ex-Date: | Feb 13, 2026 | Current Ratio: | 1.58 | EPS Y/Y TTM: | 96.48% | Oper. Margin: | 45.56% | RSI (14): | 47.56 | Volatility: | 2.84% 2.76% |
| Employees: | 50000 | Debt/Eq: | 1.65 | Sales Y/Y TTM: | 44.70% | Profit Margin: | 31.66% | Recom: | 1.51 | Target Price: | 1240.72 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 1.58 | EPS Q/Q: | 50.92% | Payout: | 26.14% | Rel Volume: | 0.62 | Prev Close: | 955.19 |
| Sales Surprise: | 7.51% | EPS Surprise: | 9.10% | Sales Q/Q: | 42.56% | Earnings: | Apr 30 BMO | Avg Volume: | 3.15M | Price: | 939.47 |
| SMA20: | 1.27% | SMA50: | -4.71% | SMA200: | 4.15% | Undervalued: 32.07% | Volume: | 1,952,362 | Change: | -1.65% | |
Graham Classic formula value: 1251.17
(P/E=8 * 1g) Min value: 701.65
(current P/E * 2g) Max value: 1922.4
Average value: 1291.74
About Lilly(Eli) & Co
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.